Laso Bio

Laso Biotherapeutics is a biotechnology company focused on developing a novel class of circularized protein therapeutics known as Laso-bodies. By utilizing a proprietary platform to engineer proteins into a circular architecture, the company aims to significantly enhance the stability, half-life, and tissue penetration of biologic drugs. This technology addresses the inherent limitations of linear proteins, such as rapid degradation and poor oral bioavailability. Laso Bio is currently advancing a pipeline of candidates targeting high-value pathways in inflammatory and autoimmune diseases. The company was a participant in the Illumina Accelerator program, highlighting its innovative approach to protein engineering.